Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100 · see citing works

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · see citing works

A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis

Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084 · see citing works

A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis

Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · see citing works

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021 · see citing works

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802 · see citing works

Mitochondrial Integrity and Function in Atherogenesis

Ballinger, S. W., Patterson, C., Knight-Lozano, C. A., Burow, D. L., Conklin, C. A., Hu, Z., Reuf, J., Horaist, C., Lebovitz, R. M., Hunter, G. C., et al. (2002) · Circulation · doi:10.1161/01.cir.0000023921.93743.89 · Cited by 478 · see citing works

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Harrison, S. A., Taub, R., Neff, G. W., Lucas, K. J., Labriola, D., Moussa, S. E., Alkhouri, N., & Bashir, M. R. (2023) · Nature Medicine · doi:10.1038/s41591-023-02603-1 · Cited by 435 · see citing works

Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk

Muzurović, E. M., Mikhailidis, D. P., & Mantzoros, C. S. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154770 · Cited by 339 · see citing works

Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia

Ladenson, P. W., Kristensen, J. D., Ridgway, E. C., OLSSON, A. G., Carlsson, B., Klein, I. L., Baxter, J. D., & Angelin, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905633 · Cited by 337 · see citing works

Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality

Younossi, Z., & Henry, L. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.005 · Cited by 334 · see citing works

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299 · see citing works

Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists

Sinha, R. A., Bruinstroop, E., Singh, B. K., & Yen, P. M. (2019) · Thyroid · doi:10.1089/thy.2018.0664 · Cited by 272 · see citing works

AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review

Wattacheril, J. J., Abdelmalek, M. F., Lim, J. K., & Sanyal, A. J. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.06.013 · Cited by 236 · see citing works

Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia

Kelly, M. J., Pietranico-Cole, S., Larigan, J. D., Haynes, N.-E., Reynolds, C. H., Scott, N., Vermeulen, J., Dvorozniak, M., Conde-Knape, K., Huang, K.-S., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4019299 · Cited by 231 · see citing works

Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam study

Bano, A., Chaker, L., Plompen, E. P. C., Hofman, A., Dehghan, A., Franco, O. H., Janssen, H. L. A., Murad, S. D., & Peeters, R. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1300 · Cited by 209 · see citing works

Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist #

Cable, E. E., Finn, P. D., Stebbins, J. W., Hou, J., Ito, B. R., van Poelje, P. D., Linemeyer, D. L., & Erion, M. D. (2008) · Hepatology · doi:10.1002/hep.22572 · Cited by 206 · see citing works

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Harrison, S. A., Bashir, M., Moussa, S. E., McCarty, K., Pablo Frias, J., Taub, R., & Alkhouri, N. (2021) · Hepatology Communications · doi:10.1002/hep4.1657 · Cited by 197 · see citing works

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease

Negi, C. K., Babica, P., Bajard, L., Vašků, J. B., & Tarantino, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 193 · see citing works

Resmetirom: An Orally Administered, Small-molecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

Karim, G., & Bansal, M. B. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.60 · Cited by 145 · see citing works

Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors

Muzurović, E., Peng, C. C., Belanger, M. J., Sanoudou, D., Mikhailidis, D. P., & Mantzoros, C. S. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.17982 · Cited by 138 · see citing works

Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States

Golabi, P., Paik, J. M., Kumar, A., Al Shabeeb, R., Eberly, K. E., Cusi, K., GunduRao, N., & Younossi, Z. M. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155642 · Cited by 113 · see citing works

Diagnosis of non-alcoholic fatty liver disease (NAFLD)

Yki‐Järvinen, H. (2016) · Diabetologia · doi:10.1007/s00125-016-3944-1 · Cited by 103 · see citing works

Thyroid Hormone Analogues: An Update

Zucchi, R. (2020) · Thyroid · doi:10.1089/thy.2020.0071 · Cited by 88 · see citing works

Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study

Kouvari, M., Valenzuela‐Vallejo, L., Guatibonza-García, V., Pοlyzos, S. A., Deng, Y., Kokkorakis, M., Agraz, M., Mylonakis, S. C., Katsarou, A., Verrastro, O., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155666 · Cited by 87 · see citing works

Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up

Choe, H. J., Moon, J. H., Kim, W. K., Koo, B. K., & Cho, N. H. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155800 · Cited by 87 · see citing works

Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life

Younossi, Z. M., Stepanova, M., Taub, R. A., Barbone, J. M., & Harrison, S. A. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.07.039 · Cited by 84 · see citing works

Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study

Peng, H., Wang, S., Wang, M., Ye, Y., Xue, E. C., Chen, X., Wang, X., Fan, M., Gao, W., Qin, X., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155220 · Cited by 83 · see citing works

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies

Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 77 · see citing works

The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study

Kouvari, M., Chrysohoou, C., Skoumas, J., Pitsavos, C., Panagiotakos, D. B., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154893 · Cited by 74 · see citing works

Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease

Pοlyzos, S. A., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.10.010 · Cited by 72 · see citing works

Spared bone mass in rats treated with thyroid hormone receptor TRβ-selective compound GC-1

Freitas, F. R., Moriscot, A. S., Jorgetti, V., Soares, A. G., Passarelli, M., Scanlan, T. S., Brent, G. A., Bianco, A. C., & Gouveia, C. H. D. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00506.2002 · Cited by 72 · see citing works

Lipid lowering with thyroid hormone and thyromimetics

Angelin, B., & Rudling, M. J. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283402e9c · Cited by 71 · see citing works

From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need

Kokkorakis, M., Boutari, C., Katsiki, N., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155664 · Cited by 65 · see citing works

The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis

Liu, S., Wang, J., Wu, S., Niu, J., Zheng, R., Bie, L., Xin, Z., Wang, S., Lin, H., Zhao, Z., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154779 · Cited by 54 · see citing works

Cell-Specific Transport and Thyroid Hormone Receptor Isoform Selectivity Account for Hepatocyte-Targeted Thyromimetic Action of MGL-3196

Hönes, G. S., Sivakumar, R. G., Hoppe, C., König, J., Führer, D., & Moeller, L. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213714 · Cited by 50 · see citing works

Thyroid hormone analogues and derivatives: Actions in fatty liver

Coppola, M. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i3.114 · Cited by 46 · see citing works

Association of fatty liver index with all-cause and disease-specific mortality: A nationwide cohort study

Chung, G. E., Jeong, S., Cho, E. J., Yoo, J., Cho, Y., Lee, K., Shin, D. W., Kim, Y. J., Yoon, J., Han, K., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155222 · Cited by 44 · see citing works

Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?

Valenzuela‐Vallejo, L., Guatibonza-García, V., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155248 · Cited by 41 · see citing works

Resmetirom for NASH: balancing promise and prudence

Hepatology, T. L. G. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00049-9 · Cited by 38 · see citing works

Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives

Yan, M., Man, S., Ma, L., & Gao, W. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155264 · Cited by 35 · see citing works

Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery

Kokkorakis, M., Katsarou, A., Katsiki, N., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155689 · Cited by 35 · see citing works

Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)

Valenzuela‐Vallejo, L., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155246 · Cited by 32 · see citing works

Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia

Jakobsson, T., Vedin, L., & Parini, P. (2017) · Drugs · doi:10.1007/s40265-017-0791-4 · Cited by 31 · see citing works

Pharmacotherapy before and after bariatric surgery

Alabduljabbar, K. A., & le Roux, C. W. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155692 · Cited by 27 · see citing works

Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A “non-invasive alternative” to liver biopsy?

Katsiki, N., Gastaldelli, A., & Mikhailidis, D. P. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154010 · Cited by 26 · see citing works

Impact of thyroid disorders on the incidence of non‐alcoholic fatty liver disease in Germany

Labenz, C., Kostev, K., Armandi, A., Galle, P. R., & Schattenberg, J. M. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12124 · Cited by 25 · see citing works

Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease

Rustgi, V. K., Duff, S., & Elsaid, M. I. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2026702 · Cited by 24 · see citing works

Sensitivity to thyroid hormones is associated with advanced fibrosis in euthyroid patients with non-alcoholic fatty liver disease: A cross-sectional study

Li, R., Zhou, L., Chen, C., Han, X., Gao, M., Cheng, X., & Li, J. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.06.021 · Cited by 22 · see citing works

The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study

Kouvari, M., Mylonakis, S. C., Katsarou, A., Valenzuela‐Vallejo, L., Guatibonza-García, V., Kokkorakis, M., Verrastro, O., Angelini, G., Markakis, G., Eslam, M., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110870 · Cited by 17 · see citing works

Thyroid function, adipokines and mitokines in metabolic dysfunction‐associated steatohepatitis: A multi‐centre biopsy‐based observational study

Kouvari, M., Valenzuela‐Vallejo, L., Axarloglou, E., Verrastro, O., Papatheodoridis, G., Mingrone, G., George, J., & Mantzoros, C. S. (2024) · Liver International · doi:10.1111/liv.15847 · Cited by 16 · see citing works

Advances in physiology, design and development of novel medications changing the landscape of obesity pharmacotherapy

Chakhtoura, M., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155531 · Cited by 15 · see citing works

A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE LIVER-SELECTIVE TR-BETA AGONIST VK2809 (MB07811) IN HYPERCHOLESTEROLEMIC SUBJECTS

Lian, B., Hanley, R. M., & Schoenfeld, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(16)31933-7 · Cited by 14 · see citing works

Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond

Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 11 · see citing works

Recent research advances in metabolism, clinical and experimental

Boutari, C., Kokkorakis, M., Stefanakis, K., Valenzuela-Vallejo, L., Axarloglou, E., Volčanšek, Š., Chakhtoura, M., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155722 · Cited by 9 · see citing works

Effects of Semaglutide on Metabolic Syndrome Parameters in Non-Diabetics: A Meta-analysis of Randomized Controlled Trials

Aggarwal, S., Bansal, S., & Aggarwal, G. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155462 · Cited by 2 · see citing works

Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?

Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169 · see citing works

The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus

Zeng, X., Varady, K. A., Wang, X., Targher, G., Byrne, C. D., Tayyem, R., Latella, G., Bergheim, I., Valenzuela, R., George, J., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156028 · Cited by 131 · see citing works

Emerging pharmacotherapies for obesity: A systematic review

Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102 · see citing works

DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 93 · see citing works

Pharmacological treatment for metabolic dysfunction–associated steatotic liver disease and related disorders: Current and emerging therapeutic options

Zhang, X., Lau, H. C.-H., & Yu, J. Q. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100018 · Cited by 94 · see citing works

The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases

Münte, E., & Hartmann, P. (2025) · Biomolecules · doi:10.3390/biom15040469 · Cited by 83 · see citing works

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies

Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 77 · see citing works

From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions

Basil, B., Myke-Mbata, B. K., Eze, O. E., & Akubue, A. U. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00187-4 · Cited by 69 · see citing works

Diet and physical exercise as key players to tackle MASLD through improvement of insulin resistance and metabolic flexibility

Mambrini, S. P., Grillo, A., Colosimo, S., Zarpellon, F., Pozzi, G., Furlan, D., Amodeo, G., & Bertoli, S. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1426551 · Cited by 70 · see citing works

Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis

Lin, R., Sun, Q., Xin, X., Ng, C. H., Valenti, L. V. C., Hu, Y., Zheng, M., & Feng, Q. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156043 · Cited by 66 · see citing works

Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis

Suvarna, R., Shetty, S., & Pappachan, J. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-70242-8 · Cited by 66 · see citing works

An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance

Armandi, A., Rosso, C., Caviglia, G. P., & Bugianesi, E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156080 · Cited by 46 · see citing works

Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism

Feng, X., Zhang, R., Yang, Z., Zhang, K., & Xing, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00019 · Cited by 41 · see citing works

Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution

Yu, W., Zhang, Y., Sun, L., Huang, W., Li, X., Xia, N. L., Chen, X., Wikana, L. P., Xiao, Y., Chen, M., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155911 · Cited by 39 · see citing works

Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment

Zisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 42 · see citing works

Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease.

Wang, S.-D., Yin, J., Liu, Z., Liu, X., Tian, G., Xin, X., Qin, Y., & Feng, X.-J. (2024) · Life Science · doi:10.1016/j.lfs.2024.123211 · Cited by 43 · see citing works

Resmetirom: The First Disease‐Specific Treatment for MASH

Mousa, A. M., Mahmoud, M., & AlShuraiaan, G. M. (2025) · International Journal of Endocrinology · doi:10.1155/ije/6430023 · Cited by 34 · see citing works

The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis

Mercado-Gómez, M., Goikoetxea‐Usandizaga, N., Kerbert, A. J. C., Gracianteparaluceta, L. U., Serrano‐Maciá, M., Lachiondo‐Ortega, S., Agudo, R. R., Gil‐Pitarch, C., Simón, J., González‐Recio, I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155952 · Cited by 30 · see citing works

FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD)

Albert, S. G., & Wood, E. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108777 · Cited by 29 · see citing works

A new perspective on liver diseases: Focusing on the mitochondria-associated endoplasmic reticulum membranes

Guo, M., Liu, R., Zhang, F., Qu, J., Yang, Y., & Li, X. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107409 · Cited by 28 · see citing works

Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management

Pοlyzos, S. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155936 · Cited by 25 · see citing works

Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals

Au, K., Zheng, M.-H., Lee, W., Ghanem, O. M., Mahawar, K. K., Shabbir, A., le Roux, C. W., Targher, G., Byrne, C. D., Yilmaz, Y., et al. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00582-z · Cited by 24 · see citing works

Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy

Guney-Coskun, M., & Başaranoğlu, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i43.4682 · Cited by 24 · see citing works

Liver sinusoidal endothelial cells: Friend or foe in metabolic dysfunction- associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis

Dai, Q., Ain, Q., Seth, N., Rooney, M., & Zipprich, A. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.01.189 · Cited by 24 · see citing works

TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial

Noureddin, M., Alkhouri, N., Lawitz, E., Kowdley, K. V., Loomba, R., Lee, L. K., Jones, C. T., Schlegel, A., Marmon, T., Anderson, K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03722-7 · Cited by 23 · see citing works

ELANE enhances KEAP1 protein stability and reduces NRF2-mediated ferroptosis inhibition in metabolic dysfunction-associated fatty liver disease

Yang, Q., Shen, X., Luo, Y., Li, R., Meng, X., Xu, P., Liu, X., Bian, D., Wang, J., Shi, J., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07603-2 · Cited by 22 · see citing works

Influence of glucagon‐like peptide‐1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta‐analysis

Passos, P. R. C., Filho, V. O. C., Noronha, M. M., Hyppólito, E. B., Saldanha, E. F., & Motta, R. V. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16752 · Cited by 21 · see citing works

Management of patients with the cardio renal liver metabolic syndrome: The need for a multidisciplinary approach in research, education and practice

Angelidi, A. M., Sanoudou, D., Hill, M. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155997 · Cited by 20 · see citing works

Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials

Lackner, C., Gouw, A. S. H., Alves, V. A. F., Arola, J. T., Bédossa, P., Behling, C. A., Brunt, E. M., Burt, A. D., Clouston, A. D., Cummings, O. W., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.09.019 · Cited by 19 · see citing works

Free Cholesterol‐Induced Liver Injury in Non‐Alcoholic Fatty Liver Disease: Mechanisms and a Therapeutic Intervention Using Dihydrotanshinone I

Shou, J., Ma, J., Wang, X., Li, X., Chen, S., Kang, B., & Shaw, P. (2024) · Advanced Science · doi:10.1002/advs.202406191 · Cited by 18 · see citing works

Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)

Shakeel, L., Shaukat, A. F., & Akilimali, A. (2025) · Health Science Reports · doi:10.1002/hsr2.70920 · Cited by 19 · see citing works

Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review

Zheng, S., Xue, C., Li, S., Zao, X., Li, X., Liu, Q., Cao, X., Wang, W., Qi, W., Zhang, P., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1381712 · Cited by 19 · see citing works

Puerarin: a hepatoprotective drug from bench to bedside

He, Y.-X., Liu, M., Wu, H., Lan, Q., Liu, H., Mazhar, M., Xue, J.-Y., Zhou, X., Chen, H., & Li, Z. (2024) · Chinese Medicine · doi:10.1186/s13020-024-01011-y · Cited by 18 · see citing works

Caffeine ameliorates metabolic-associated steatohepatitis by rescuing hepatic Dusp9

Xin, X., Chen, C., Xu, X., Lv, S., Sun, Q., An, Z., Chen, Y., Xiong, Z., Hu, Y., & Feng, Q. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103499 · Cited by 18 · see citing works

PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression

Antwi, M. B., Lefere, S., Clarisse, D., Koorneef, L. L., Heldens, A., Onghena, L., Decroix, K., Fijałkowska, D., Thommis, J., Hellemans, M., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156128 · Cited by 17 · see citing works

Regional gray matter changes in steatotic liver disease provide a neurobiological link to depression: A cross-sectional UK biobank cohort study.

Arold, D., Bornstein, S. R., Perakakis, N., Ehrlich, S., & Bernardoni, F. (2024) · Metabolism: Clinical and Experimental · doi:10.1016/j.metabol.2024.155983 · Cited by 17 · see citing works

Concordance of vibration-controlled transient elastography and magnetic resonance elastography for fibrosis staging in patients with metabolic dysfunction-associated steatotic liver disease

Mathur, A., Ozkaya, E., Rosberger, S., Sigel, K. M., Doucette, J. T., Bansal, M. B., & Taouli, B. A. (2025) · European Radiology · doi:10.1007/s00330-025-11533-0 · Cited by 17 · see citing works

New drug therapies for metabolic dysfunction-associated steatohepatitis

Chiang, J. Y. L. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.001 · Cited by 16 · see citing works

Polyphenols from Foxtail Millet Improve Non-Alcoholic Fatty Liver Disease by Regulating Intestinal Microbiome in Mice

Israr, G., An, Y., Qiao, Q., He, S., & Li, Z. (2024) · Foods · doi:10.3390/foods13111683 · Cited by 16 · see citing works

NORAD exacerbates metabolic dysfunction-associated steatotic liver disease development via the miR-511-3p/Rock2 axis and inhibits ubiquitin-mediated degradation of ROCK2

Zhang, X., Chen, T., Li, Z., Wan, L., Zhou, Z., Xu, Y., Yan, D., Zhao, W., & Chen, H. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156111 · Cited by 16 · see citing works

Upregulation of Hepatic Glutathione S-Transferase Alpha 1 Ameliorates Metabolic Dysfunction-Associated Steatosis by Degrading Fatty Acid Binding Protein 1

Jiang, J., Li, H., Tang, M., Lei, L., Li, H.-Y., Dong, B., Li, J., Wang, X., Sun, H., Li, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105086 · Cited by 15 · see citing works

Resmetirom for MASH patients with diabetes: challenges and opportunities in the real world

Lian, L., Targher, G., Byrne, C. D., Liu, W., & Zheng, M. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155935 · Cited by 15 · see citing works

Gallic acid mitigates high-fat and high-carbohydrate diet-induced steatohepatitis by modulating the IRF6/PPARγ signaling pathway

Qiu, J., Fu, L., Xue, Y., Yang, Y., Qiao, F., Zhu, W., Gao, Y., Fang, M., Liu, Y., Gao, Z., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1563561 · Cited by 13 · see citing works

LEADS – a comprehensive human liver-on-a-chip for non-alcoholic steatohepatitis (NASH) drug testing

Balachander, G. M., Ng, I. C., Pai, R. R., Mitra, K., Tasnim, F., Lim, Y. S., Kwok, R., Song, Y., Yaw, L. P., Quah, C. B., et al. (2025) · Lab on a Chip · doi:10.1039/d5lc00221d · Cited by 15 · see citing works

Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research

Książek, E., Goluch, Z., & Bochniak, M. (2024) · Nutrients · doi:10.3390/nu16172940 · Cited by 13 · see citing works

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Is an Independent Risk Factor for the Development of Ischemic Heart Disease ― A 10-Year Cohort Study ―

Ogawa, T., Sato, T., Tanaka, M., Akiyama, Y., Nakata, K., Kouzu, H., Mori, K., Aida, H., Kawaharata, W., Hosaka, I., et al. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0019 · Cited by 14 · see citing works

Recent advances in targeting obesity, with a focus on TGF-β signaling and vagus nerve innervation

John, S., Bhowmick, K., PARK, A. W., Huang, H., Yang, X., & Mishra, L. (2025) · Bioelectronic Medicine · doi:10.1186/s42234-025-00172-x · Cited by 15 · see citing works

The multifaceted effects of semaglutide: exploring its broad therapeutic applications

Alkhatib, M., Almasri, N., Alshwayyat, S., Almahariq, H., Hammadeh, B. M., Taimeh, Z., Alkhatib, L., Alshwayat, A. R. I., Saadeh, N. A., & Al‐kurdi, M. A. (2025) · Future Science OA · doi:10.1080/20565623.2025.2483607 · Cited by 13 · see citing works

Nanoformulations for the diagnosis and treatment of metabolic dysfunction-associated steatohepatitis

Qin, X., & Liu, J. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.06.014 · Cited by 12 · see citing works

Expanding diagnostic and therapeutic horizons for MASH: Comparison of the latest and conventional therapeutic approaches

Anastasiou, G., Stefanakis, K., Hill, M. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156044 · Cited by 12 · see citing works

Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease

Li, F., Yuan, R., Zhang, J., Su, B., & Qi, X. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101025 · Cited by 12 · see citing works

Targeting Polymeric Nanoparticles to Specific Cell Populations in the Liver

Harkins, L., Vilarinho, S., & Saltzman, W. M. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00712 · Cited by 11 · see citing works

GDF-15 improves the predictive capacity of steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignancies

Kokkorakis, M., Folkertsma, P., Forte, J. C., Wolffenbuttel, B. H. R., van Dam, S., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156047 · Cited by 11 · see citing works

A ROS/ultrasound dual-responsive nanocarrier enhances drug penetration for ameliorating metabolic dysfunction-associated steatohepatitis

Liang, S., Lin, M., Wang, J., Wei, H., Huang, S., Yin, T., Xiao, H. P., Shuai, X., & Ren, J. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.07.010 · Cited by 16 · see citing works

Revisiting liver metabolism through acetyl-CoA carboxylase inhibition

Pérez-Díaz, A. J., Núñez‐Sánchez, M. Á., & Ramos‐Molina, B. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.010 · Cited by 10 · see citing works

Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography

Aguado, D. M., Sierra, J. M. C., Villalba, A., Siddiqi, H., VALLEJO-VIGO, R. M., Lara‐Romero, C., Martín-Fernández, M., Fernández-Patón, M., Alfaro‐Cervelló, C., Crespo, A., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.10.014 · Cited by 10 · see citing works

Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis

Fan, X., Wang, Y., Wang, Y., Duan, H., Du, Y., Pan, T., & Zhong, X. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00898-z · Cited by 10 · see citing works

Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1

Lee, Y. H., Lee, J., Jeong, J., Park, K., Baik, B., Kwon, Y., Kim, K., Khim, K. W., Ji, H., Lee, J. Y., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156266 · Cited by 12 · see citing works

FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data

Boutari, C., Triantafyllou, A., Papalavrentios, L., Goulis, I., & Sinakos, E. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128374854250709050425 · Cited by 10 · see citing works

PDCD4 deficiency in hepatocytes exacerbates nonalcoholic steatohepatitis through enhanced MHC class II transactivator expression

Lu, K., He, L., Guo, Z., Li, M., Cheng, X., Liu, S., Zhang, T., Chen, Q., Zhao, R., Yang, L., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156036 · Cited by 9 · see citing works

Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs

Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lange, P. W., Fitzpatrick, J. A., Vaz, K., Lubel, J. S., Hodge, A. D., Ryan, J. L., McNeil, J. J., et al. (2025) · Nutrients · doi:10.3390/nu17132189 · Cited by 11 · see citing works

Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease

Desalegn, H., Farias, R., Hudson, D., Idalsoaga, F. J., Cabrera, D., Díaz, L. A., & Arab, J. P. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.30 · Cited by 8 · see citing works

Lubiprostone Reduces Fat Content on MRI ‐ PDFF in Patients With MASLD : A 48‐Week Randomised Controlled Trial

El‐Kassas, M., Mostafa, H., Abdellatif, W., Shoman, S., Esmat, G., Brahmania, M., Liu, H., & Lee, S. S. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18478 · Cited by 8 · see citing works

The Biology and Clinical Implications of PCSK7

Sachan, V., Susan‐Resiga, D., Lam, K., & Seidah, N. G. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae031 · Cited by 8 · see citing works

Monitoring the liver as a part of the cardio-renal-metabolic continuum – What is cooking and burning with non-invasive tests and treatment options?

Volčanšek, Š., Janež, A., Rizzo, M., & Muzurović, E. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108875 · Cited by 7 · see citing works

The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis

Ge, Z., Wu, Q., Lv, C., & He, Q. (2025) · Immunology · doi:10.1111/imm.13943 · Cited by 7 · see citing works

The African Middle East Association of Gastroenterology (AMAGE) clinical practice guidelines for the diagnosis and management of metabolic dysfunction associated fatty liver disease

Fouad, Y., Elwakil, R., Sanai, F. M., Ojo, O. S., Awadhi, S. A., Ocama, P., Abdelkader, N. A., Al‐Busafi, S. A., Awuku, Y. A., Zaki, S., et al. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102180 · Cited by 7 · see citing works

Letter: Drug interaction in resmetirom times

Zhou, X., Liu, W., Targher, G., Byrne, C. D., & Zheng, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18062 · Cited by 7 · see citing works

Liver-specific thyroid hormone receptor-β agonism alleviates alcoholic steatohepatitis (ASH) in mice

Shahi, A., Yadav, A., Rajak, S., Raza, S., Tewari, A., Gupta, P., & Sinha, R. A. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150742 · Cited by 7 · see citing works

Thyroid Hormone-Mediated Selective Autophagy and Its Implications in Countering Metabolic Dysfunction-Associated Steatotic Liver Disease

Sinha, R. A. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2068 · Cited by 7 · see citing works

Unlocking the potential of THR-β agonist therapies: resmetirom’s chemistry, biology, and patent insights

Dahiya, K., Palkar, M. B., & Sharma, S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03880-y · Cited by 7 · see citing works

Herbal mixture of Platycodon grandiflorum, Cinnamomum cassia, and Asiasarum sieboldii extracts protects against NASH progression via regulation of hepatic steatosis, inflammation, and apoptosis

Zhang, S., Lee, H., Ahn, H. R., Kim, H., Yang, H. O., Yoo, K., Lee, G., & Kim, J. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157077 · Cited by 6 · see citing works

Semaglutide, the first approved GLP-1 receptor agonist for the management of metabolic dysfunction-associated steatohepatitis

Boutari, C., Hill, M. A., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156397 · Cited by 6 · see citing works

D-Psicose mitigates NAFLD mice induced by a high-fat diet by reducing lipid accumulation, inflammation, and oxidative stress

Tan, J., Sun, W., Dong, X., He, J., Ali, A. M. M., Chen, M., Zhang, L., Wu, L., & Shao, K. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1574151 · Cited by 5 · see citing works

Dual-Target Insight into Drug Discovery from Natural Products as Modulators of GLP-1 and the TXNIP–Thioredoxin Antioxidant System in Metabolic Syndrome

Agu, P. C., Yudas, A. F., & Lu, J. (2025) · Antioxidants · doi:10.3390/antiox14111364 · Cited by 5 · see citing works

Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults

Reinson, T., Bilson, J., Childs, C. E., Buchanan, R. M., Targher, G., & Byrne, C. D. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002038 · Cited by 8 · see citing works

A new liver-targeted agonist of thyroid hormone receptor beta resmetirom in treating MASLD/MASH: From mechanism to therapy

Liu, M., Ma, Y., Cheang, W. S., Su, Z., & Xu, S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.011 · Cited by 5 · see citing works

Mechanism Study of Xiaoyao San against Nonalcoholic Steatohepatitis-Related Liver Fibrosis Based on a Combined Strategy of Transcriptome Analysis and Network Pharmacology

Yan, D., Zhang, X., Ma, C., Huang, W., Hao, M., & Xie, L. (2024) · Pharmaceuticals · doi:10.3390/ph17091128 · Cited by 5 · see citing works

Impact of Short-Term Lipid Overload on Whole-Body Physiology

Keles, U., Kalem-Yapar, N. E., Hultén, H., Zhao, L. N., & Kaldis, P. (2024) · Molecular and Cellular Biology · doi:10.1080/10985549.2024.2438814 · Cited by 6 · see citing works

Fluorofenidone attenuates choline-deficient, l-amino acid-defined, high-fat diet-induced metabolic dysfunction-associated steatohepatitis in mice

Zhang, J., Wang, Q., Zhou, N., Liu, J., Tao, L., Peng, Z., Hu, G., Wang, H., Fu, L., & Peng, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-94401-7 · Cited by 5 · see citing works

Targeted therapeutic strategies as alternative and sustainable treatment options for obesity-induced steatohepatitis

Mabuda, T. I., Sibuyi, N. R. S., Fadaka, A. O., Meyer, M., Madiehe, A. M., & Gabuza, K. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09980-7 · Cited by 5 · see citing works

The Cholate Challenge Test Quantified Baseline Functional Heterogeneity and Improvement in Response to Resmetirom in MASH-related Child-Pugh A Cirrhosis

Alkhouri, N., McRae, M. P., Taub, R. A., Hill, B., Imperial, J. C., Kittelson, J., Moussa, S. E., & Everson, G. T. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100785 · Cited by 4 · see citing works

MASLD and the cardiovascular-kidney-liver-metabolic syndrome

Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 6 · see citing works

BMDM-derived ORP8 suppresses lipotoxicity and inflammation by relieving endoplasmic reticulum stress in mice with MASH

Chen, Y., Xie, K.-J., Chen, C., Wang, X.-H., Ma, C.-C., Huang, Z.-X., Jiao, Y., & Yu, W.-F. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01275-6 · Cited by 4 · see citing works

Obtusifolin mitigates CCl4-induced inflammation and liver fibrosis by modulating the ROCK2/ Cofilin-1 / NFκB pathway

Panneerselvam, S., Sharma, N., & Andugulapati, S. B. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178479 · Cited by 4 · see citing works

Deciphering cytochrome P450 reductase role in MASLD: molecular mechanisms and pathophysiological implications

Baptista, C., Esteves, F., Fallowfield, J. A., Kendall, T. J., Nelson, L. J., & Kranendonk, M. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01202-y · Cited by 4 · see citing works

Metabolic dysfunction-associated steatotic liver disease and malignancies: Unmasking a silent saboteur

Pοlyzos, S. A., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156253 · Cited by 4 · see citing works

Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques

Srikanth, P., Shaik, K. M., Patibandla, V., Kumar, D., & Nandi, S. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101425 · Cited by 3 · see citing works

Cell and gene therapeutic approaches in non-alcoholic fatty liver disease

Poudineh, M., Mohammadyari, F., Parsamanesh, N., Jamialahmadi, T., Kesharwani, P., & Sahebkar, A. (2025) · Gene · doi:10.1016/j.gene.2025.149466 · Cited by 3 · see citing works

Effect of resmetirom on lipid profile and adiponectin levels

Simental‐Mendía, L. E., Simental-Mendía, M. A., Barragán‐Zuñiga, L. J., & Navarro-Tinoco, L. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106440 · Cited by 3 · see citing works

Multi-strain synbiotic and lifestyle modifications on patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a randomized double-blinded placebo-controlled trial

Dinevari, M. F., Abbasian, S., Sarmadian, A. J., Vaezi, T., Vaezi, T., Nikniaz, Z., & Riazi, A. R. (2026) · European journal of medical research · doi:10.1186/s40001-026-03901-3 · Cited by 3 · see citing works

Effectiveness of Resmetirom in Reducing Cholesterol Levels in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis

Bejitual, E., Awais, M. F., Modi, D., Gul, U., Obeidat, K., Ahmed, N., Waheed, M. D., & Hirani, S. (2024) · Cureus · doi:10.7759/cureus.70859 · Cited by 3 · see citing works

Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study

Huang, C., Wang, C.-L., Wu, V. C., Hsieh, Y., Wu, C.-L., Zeng, Z.-F., Huang, Y., Hsu, C., Chien, R., & Chang, S. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2573146 · Cited by 3 · see citing works

Altered kidney function in fatty liver disease: confronting the “MAFLD-renal syndrome”

Ashi, S. A., Rizvi, A. A., & Rizzo, M. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1539117 · Cited by 4 · see citing works

An Integration of RNA Sequencing and Network Pharmacology Approaches Predicts the Molecular Mechanisms of the Huo-Xue-Shen Formula in the Treatment of Liver Fibrosis

Jiang, K., Bao, J., Lou, Z., Liu, F., Xu, K., & Kwan, H. Y. (2025) · Pharmaceuticals · doi:10.3390/ph18020227 · Cited by 3 · see citing works

Computational modelling in liver system and liver disease

Liao, Y., Davies, N. A., & Bogle, I. D. L. (2025) · Physical Sciences Reviews · doi:10.1515/psr-2024-0051 · Cited by 3 · see citing works

Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?

Smadi, K. A., Qureshi, A., Ashouri, B., & Kayali, Z. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2388592 · Cited by 3 · see citing works

Identification of CDKN1A as a potential key risk factor in MASLD progression

Deng, L., Deng, J., Luo, L., Yang, H., Sun, M., Yucheng, G., Liu, Q., Ngowi, E. E., Zhou, Y., Zhang, R., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202402942r · Cited by 2 · see citing works

An engineered adipose formulation decreases hepatic inflammation and fibrosis in a rodent model of metabolic dysfunction-associated steatotic liver disease

Choi, Y., Ma, Y., Tom, S., Danilkovitch, A., & Yu, L. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1579062 · Cited by 2 · see citing works

Translating Trial to Treatment: A Scoping Review of Resmetirom First Year in Real-World Use for Moderate to Advanced Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis

Vats, K., & Alam, M. M. (2025) · Cureus · doi:10.7759/cureus.90268 · Cited by 2 · see citing works

Resmetirom: A Worthy Challenger in Nonalcoholic Steatohepatitis at Last?

Govindraj, L. (2024) · Amrita Journal of Medicine · doi:10.4103/amjm.amjm_47_24

What is new in metabolic dysfunction‐associated steatotic liver disease?

Tan, K. C. B. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70003

Resmetirom in metabolic dysfunction-associated steatohepatitis: a profile of its use

Blair, H. A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01183-z

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)

IDRIS, I. R. (2024) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.92

Update on Newly Federal Drug Administration-Approved Drug, Resmetirom: A Practical Perspective

Barritt, A. S., & Stine, J. G. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002922 · Cited by 5 · see citing works